Disease · MONDO_0007915

systemic lupus erythematosus

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. systemic lupus erythematosus. Diseases, record MONDO_0007915. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007915

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: systemic lupus erythematosus; Open Targets
Open Targets ID: MONDO_0007915; Open Targets
Other names: Disease, Libman-Sacks, LIBMAN SACKS DIS, Libman Sacks Disease, Lupus Erythematosus Disseminatus, SLE, SLE - lupus erythematosus, systemic, disseminated lupus erythematosus, lupus, lupus erythematosus, systemic, systemic lupus erythematosus (disease), systemic lupus erythematosus susceptibility to; Open Targets
Disease Ontology: DOID:9074; Disease Ontology
MeSH: D008180; MeSH
NCI Thesaurus: C3201; NCI Thesaurus
Orphanet: ORPHA:536; Orphanet
Highest stage of its drugs: Approval, for 8 of its 207 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs207

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BELIMUMAB	CHEMBL1789843	Antibody	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	41	37	37	Drugs and targets
ANIFROLUMAB	CHEMBL2364653	Antibody	Approval	EMA Human Drugs, FDA and TTD	21	18	18	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	13	12	9	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Approval	DailyMed	4	3	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	4	2	0	Drugs and targets
HYDROXYCHLOROQUINE SULFATE	CHEMBL1690	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
CORTISONE ACETATE	CHEMBL1650	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	27	27	27	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets

1 to 10 of 207

See all 207 drugs

Targets184

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	14	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
JAK1	Janus Kinase (JAK)	8	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Phase 3	https://conductscience.org/library/genes/3716	Drugs and targets
BTK	Tyrosine-protein kinase BTK	6	Tyrosine-protein kinase BTK inhibitor	Phase 2	https://conductscience.org/library/genes/695	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	6	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
TYK2	Janus Kinase (JAK)	6	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/7297	Drugs and targets
CD19	B-lymphocyte antigen CD19	5	B-lymphocyte antigen CD19 binding agent; B-lymphocyte antigen CD19 cross-linking agent; B-lymphocyte antigen CD19 inhibitor	Phase 2	https://conductscience.org/library/genes/930	Drugs and targets
JAK2	Janus Kinase (JAK)	5	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Phase 3	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Janus Kinase (JAK)	5	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Phase 3	https://conductscience.org/library/genes/3718	Drugs and targets
TNFSF13B	Tumor necrosis factor ligand superfamily member 13B	5	Tumor necrosis factor ligand superfamily member 13B inhibitor	Approval	https://conductscience.org/library/genes/10673	Drugs and targets
ESR1	Estrogen receptor	4	Estrogen receptor agonist; Estrogen receptor alpha agonist; Estrogen receptor alpha antagonist; Estrogen receptor degrader	Phase 3	https://conductscience.org/library/genes/2099	Drugs and targets

1 to 10 of 184

See all 184 targets

Trials379

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01729455	Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry		3,138	2026-03-20	Systemic Lupus Erythematosus	BELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01488708	On Open-Label Study in Participants With Systemic Lupus Erythematosus	Phase 3	1,518	2018-05-17	Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease	TABALUMAB	Its record names the disease	ClinicalTrials.gov
NCT01408576	Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus	Phase 3	1,250	2018-10-03	Systemic Lupus Erythematosus	EPRATUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01196091	A Study of LY2127399 in Participants With Systemic Lupus Erythematosus	Phase 3	1,164	2018-06-12	Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease	TABALUMAB	Its record names the disease	ClinicalTrials.gov
NCT03843125	A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)	Phase 3	1,147	2023-05-16	Systemic Lupus Erythematosus	BARICITINIB	Its record names the disease	ClinicalTrials.gov
NCT01205438	A Study of LY2127399 in Participants With Systemic Lupus Erythematosus	Phase 3	1,124	2018-06-19	Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease	TABALUMAB	Its record names the disease	ClinicalTrials.gov
NCT00424476	A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)	Phase 3	865	2011-05-05	Systemic Lupus Erythematosus	BELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01484496	A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)	Phase 3	839	2017-07-25	Systemic Lupus Erythematosus	BELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01283139	A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus	Phase 2	834	2016-07-11	Systemic Lupus Erythematosus	SIFALIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT03616912	A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus	Phase 3	830	2023-01-30	Systemic Lupus Erythematosus	BARICITINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 379

See all 379 trials

Comparisons in its trials125

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Benlysta vs Non-Benlysta: deaths from any cause	48 of 1,924	29 of 881	2,805	NCT01729455	Trial comparisons
Benlysta vs Non-Benlysta: serious adverse events	248 of 1,924	108 of 881	2,805	NCT01729455	Trial comparisons
Belimumab 10 mg/kg (DB Phase) vs Placebo (DB Phase): Number of Participants With Severe AEs [DB Phase]	46 of 331	37 of 165	496	NCT01632241	Trial comparisons
Belimumab 10 mg/kg (DB Phase) vs Placebo (DB Phase): Number of Participants With AEs Leading to Treatment Discontinuation [DB Phase]	22 of 331	12 of 165	496	NCT01632241	Trial comparisons
Anifrolumab 300 mg vs Placebo: Number of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements	45 of 180	45 of 182	362	NCT02446899	Trial comparisons
Anifrolumab 300 mg vs Placebo: Number of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests	72 of 180	87 of 182	362	NCT02446899	Trial comparisons
Anifrolumab 300 mg vs Placebo: Number of Participants With One or More Adverse Events (AEs)	162 of 180	154 of 182	362	NCT02446899	Trial comparisons
Anifrolumab 300 mg vs Placebo: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52	86 of 180	57 of 182	362	NCT02446899	Trial comparisons
Anifrolumab 300 mg vs Placebo: Number of Participants With One or More Adverse Events of Special Interest (AESIs)	29 of 180	20 of 182	362	NCT02446899	Trial comparisons
Anifrolumab 300 mg vs Placebo: deaths from any cause	1 of 180	0 of 182	362	NCT02446899	Trial comparisons

1 to 10 of 125

See all 125 comparisons in its trials

Papers from its trials264

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35065636	RESULT	1	PubMed
34857051	RESULT	1	PubMed
34754179	RESULT	1	PubMed
33380211	RESULT	1	PubMed
33348854	RESULT	1	PubMed
33152483	RESULT	1	PubMed
33084768	RESULT	1	PubMed
32929825	RESULT	1	PubMed
32755035	RESULT	1	PubMed
32528227	RESULT	1	PubMed

1 to 10 of 264

See all 264 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007915

GET https://conductscience.org/api/diseases/v1/MONDO_0007915/drugs?page=2

API reference For AI assistants